Navigation Links
Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling
Date:4/14/2008

icin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the 'context of vulnerability'.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2008)...s innovation leadership and long-term commitment t...Nov. 24 Schering-Plough ...al update on boceprevir, its lead investigational ...hase III development. The company believes bocepr...best-in-class protease inhibitor for treating chro...
(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...
(Date:11/24/2008)...Nov. 24 GeneThera, Inc.,...gin offering its Real Time,PCR test for Johne,s d..., GeneThera is set to begin offering its Jo...of 2009. According to GeneThera Chairman, Dr. Ton... real time PCR test for Johne,s disease,called H...
(Date:11/24/2008).... 24 Medarex, Inc. (Nas...hase 1b clinical trial for MDX-1106 (ONO-4538: dev...fully human anti-PD-1 antibody for the treatment o... pathway may play an important role in tumor evasi...lso promote the persistence of certain chronic vir...
Breaking Medicine Technology:Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 2Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 3Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 4Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 1Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 2Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 3New class of drug offers hope to treatment resistant AIDS patients 777 1New class of drug offers hope to treatment resistant AIDS patients 777 2New class of drug offers hope to treatment resistant AIDS patients 777 3Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 1Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 1Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 3
... HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGeni...n, Chief Scientific Officer will,present an update...using the Company,s proprietary synDNA(TM) technol... in Malaga, Spain between May 23,and May 25., Dr. ...ts of,synDNA(TM) based vaccines in mice, rabbits a...
... EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - N...ed today results of its,pivotal Phase III trauma t...oxygen-carrying red blood cell substitute. The,tri...he treatment,of life-threatening red blood cell lo...s are not available, not for use,interchangeably w...
Other Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8
(Date:12/1/2008)...eedling, steroids effective against plantar fasci... 1 (HealthDay News) -- Italian researchers say the...atment for the painful foot condition known as pla...eedling" and steroid injections guided by ultrasou...95 percent success rate in tackling a condition th...
(Date:12/1/2008)...DRIA, Va., Dec. 1 Today..., nearly 7,000 people die each day due to HIV/AI...y of awareness and outreach to help people worldwi...eme for World AIDS Day 2008 is You Can Make a Di...ging people together to talk about HIV as well as ...
(Date:12/1/2008)...O, Dec. 1 Condell Healt...enter, a 283-bed hospital in Libertyville - after ...edicare and Medicaid payments - has agreed without... of Illinois$36 million as a result of filing fals...itzgerald, U.S. Attorney for the Northern District...
(Date:12/1/2008)...m infants already at higher risk for SIDS and this... Dec. 1 (HealthDay News) -- Premature infants ofte...sts during the first six months of life and may be... infant death syndrome (SIDS), Australian research...is a profound drop in blood pressure during sleep,...
Breaking Medicine News(10 mins):Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2Health News:Condell Health Network and Medical Center to Pay $36 Million Settlement After Self-Reporting Possible Health-Care Fraud 2Health News:Preemies' Low Blood Pressure Linked to SIDS 2Health News:Preemies' Low Blood Pressure Linked to SIDS 3
...l contamination could have been the cause of the r...to the contact lens solution according to research...ntrol and Prevention received multiple reports of ...s, the Bausch & Lomb solution Renu with MoistureLo...
... seem to indicate that recurrent strokes are more ...een published in the September 2006// issue of Ann...m/journal/ana), the official journal of the Americ...rrence of stroke in Mexican Americans (MAs) and fo...
...tal and Medical Admission Test (DMAT) conducted re...eports of the question paper having been leaked// ...ember Justice Chandresh Bhushan Committee, formed ...larities, decided that the examination be held afr...
...frican countries have partnered with Indian scient...ased approach to caring and treating// newborn bab...EF said in a statement released here. Facilitated...ICEF), decision-makers from Ethiopia, Kenya, Ugand...
Other Medicine News:Health News:Corneal infections Linked to External Contamination 2Health News:Recurrence Of Stroke More Common In Mexican American 2Health News:Medical Admission Test Cancelled Over Leakage Reports 2Health News:Indian Scientist to Help Reduce Infant Mortality in Africa: UNICEF 2
Indications For Usage: , Airway management during surgical procedures , Long-term ventilatory management
...ne, battery-powered disposable, lightweight and co...e, capable of intravenous application and irrigati... help prevent fluid-induced hypothermia. The Ther...g;C (100.4°F) 3°C at a flow rate of 2 to 1...
The NormoFlow™ System is the only effective solution for keeping patients warm during high volume surgical irrigation, especially urologic procedures. Patients leave the operating room warm, re
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets.
Medicine Products: